StockData

Onconetix vs Rafael

ONCO and RFL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ONCO and RFL compare

Rafael is the larger company, worth 4.0 times as much as Onconetix ($47.7M against $11.8M).

Rafael grew revenue faster over the last twelve months (−4.7% versus −51.3% for Onconetix).

Onconetix keeps more of each dollar of sales as profit, with a net margin of −1579% compared with −3391% at Rafael.

Rafael scores higher on the StockData Score (5 against 3 for Onconetix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricONCORFL
Size and price
Market cap$11.8M$47.7M
Share price$3.00$0.913
Change, 1 year−99.7%−25.1%
Change, 5 years−100.0%−84.5%
Beta (5Y)–0.58
Employees1217
StockData Score
Total score35 (better)
Valuation score11
Growth score11
Performance score02 (better)
Health score11
Dividend score00
Valuation
P/S18.3× (better)54.5×
P/B0.9×0.7× (better)
FCF yield–−62.9%
Growth
Revenue growth (TTM)−51.3%−4.7% (better)
Revenue growth, 5Y average–1.7%
Profitability
Gross margin80.4%–
Operating margin−2525% (better)−3823%
Net margin−1579% (better)−3391%
FCF margin–−3431%
Return on equity−105%−36.9% (better)
Return on invested capital−196%−61.5% (better)
Financial health
Interest coverage−52.4× (better)−100.3×
Current ratio2.212.35 (better)
Altman Z-score−12.36−2.94 (better)
Piotroski F-score6 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions1.7%7.5%
Held by insiders40.3%39.2%
Insider net buying, 12 months$8.4K–
Short interest, % of float40.6%0.92%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.